title: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01.
abstract: OBJECTIVE
  To determine the response rate of weekly docetaxel in women with relapsed epithelial ovarian cancer previously treated with paclitaxel and at least one line of platinum-based chemotherapy.
  
  
  METHODS
  In this multi-center phase II trial, 37 patients with relapsed disease were enrolled and treated with weekly docetaxel at 35 mg/m for 5 out of 6 consecutive weeks. Two patient cohorts were considered, those who progressed or relapsed within 4 months (N=7) or at greater than 4 months (N=30) from the time of completing their last course of paclitaxel.
  
  
  RESULTS
  Patients in both cohorts received a median of 2 cycles of treatment (range; 1-4). In evaluable patients, the combined overall response rate, using both CA125 and RECIST response criteria was 18.9% (7/37; 95% CI; 10-34%). The combined overall progression-free survival was 3.1 months (95% CI; 2.5-3.8), and the combined overall survival was 12.3 months (95% CI; 8.2-16.4). Treatment was generally well tolerated with the only grade 4 toxicity being skin toxicity (3%). The most common grade 3 toxicities were fatigue (14%) and watery eyes (8%) with grade 3 neutropenia observed in only 5% of patients.
  
  
  CONCLUSIONS
  Weekly docetaxel is well tolerated and has activity in patients with relapsed ovarian cancer previously treated with platinum and paclitaxel.
authors.affiliation: Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
authors.forename: A V
authors.initials: AV
authors.lastname: Tinker
authors.forename: V
authors.initials: V
authors.lastname: Gebski
authors.forename: B
authors.initials: B
authors.lastname: Fitzharris
authors.forename: M
authors.initials: M
authors.lastname: Buck
authors.forename: R
authors.initials: R
authors.lastname: Stuart-Harris
authors.forename: P
authors.initials: P
authors.lastname: Beale
authors.forename: A
authors.initials: A
authors.lastname: Goldrick
authors.forename: D
authors.initials: D
authors.lastname: Rischin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel